Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status.
Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen CD, Tuskova L, Hoferkova E, Mraz M, Helman K, Curik N, Machova Polakova K, Anděra L, Trněný M, Klener P.
Dolnikova A, et al. Among authors: mraz m.
Blood Adv. 2024 May 7:bloodadvances.2024012906. doi: 10.1182/bloodadvances.2024012906. Online ahead of print.
Blood Adv. 2024.
PMID: 38713893